|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Bartel DP: MicroRNAs: target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Filipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of post-transcriptional regulation by
microRNAs: are the answers in sight? Nature reviews Genetics.
9:102–114. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nature reviews Cancer.
6:259–269. 2006. View
Article : Google Scholar
|
|
5
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Slack FJ and Weidhaas JB: MicroRNA in
cancer prognosis. N Engl J Med. 359:2720–2722. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Grimson A, Farh KK, Johnston WK,
Garrett-Engele P, Lim LP and Bartel DP: MicroRNA targeting
specificity in mammals: determinants beyond seed pairing. Mol Cell.
27:91–105. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ling B, Wang GX, Long G, Qiu JH and Hu ZL:
Tumor suppressor miR-22 suppresses lung cancer cell progression
through post-transcriptional regulation of ErbB3. J Cancer Res Clin
Oncol. 138:1355–1361. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pandey DP and Picard D: miR-22 inhibits
estrogen signaling by directly targeting the estrogen receptor
alpha mRNA. Mol Cell Biol. 29:3783–3790. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xiong J, Yu D, Wei N, et al: An estrogen
receptor alpha suppressor, microRNA-22, is downregulated in
estrogen receptor alpha-positive human breast cancer cell lines and
clinical samples. FEBS J. 277:1684–1694. 2010. View Article : Google Scholar
|
|
11
|
Patel JB, Appaiah HN, Burnett RM, et al:
Control of EVI-1 oncogene expression in metastatic breast cancer
cells through microRNA miR-22. Oncogene. 30:1290–1301. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang J, Yang Y, Yang T, et al:
microRNA-22, downregulated in hepatocellular carcinoma and
correlated with prognosis, suppresses cell proliferation and
tumourigenicity. Br J Cancer. 103:1215–1220. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li J, Liang S, Jin H, Xu C, Ma D and Lu X:
Tiam1, negatively regulated by miR-22, miR-183 and miR-31, is
involved in migration, invasion and viability of ovarian cancer
cells. Oncol Rep. 27:1835–1842. 2012.PubMed/NCBI
|
|
14
|
Li J, Liang S, Yu H, Zhang J, Ma D and Lu
X: An inhibitory effect of miR-22 on cell migration and invasion in
ovarian cancer. Gynecol Oncol. 119:543–548. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li J, Zhang Y, Zhao J, Kong F and Chen Y:
Overexpression of miR-22 reverses paclitaxel-induced
chemoresistance through activation of PTEN signaling in p53-mutated
colon cancer cells. Mol Cell Biochem. 357:31–38. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bar N and Dikstein R: miR-22 forms a
regulatory loop in PTEN/AKT pathway and modulates signaling
kinetics. PloS One. 5:e108592010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yamakuchi M, Yagi S, Ito T and Lowenstein
CJ: MicroRNA-22 regulates hypoxia signaling in colon cancer cells.
PloS One. 6:e202912011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Alvarez-Diaz S, Valle N, Ferrer-Mayorga G,
et al: MicroRNA-22 is induced by vitamin D and contributes to its
antiproliferative, antimigratory and gene regulatory effects in
colon cancer cells. Hum Mol Genet. 21:2157–2165. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Strumane K, Rygiel TP and Collard JG: The
Rac activator Tiam1 and Ras-induced oncogenesis. Methods Enzymol.
407:269–281. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jin H, Li T, Ding Y, et al: Methylation
status of T-lymphoma invasion and metastasis 1 promoter and its
overexpression in colorectal cancer. Hum Pathol. 42:541–551. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Huang J, Ye X, Guan J, et al: Tiam1 is
associated with hepatocellular carcinoma metastasis. Int J Cancer.
132:90–100. 2012. View Article : Google Scholar
|
|
22
|
Yang W, Lv S, Liu X, Liu H and Hu F:
Up-regulation of Tiam1 and Rac1 correlates with poor prognosis in
hepatocellular carcinoma. Jpn J Clin Oncol. 40:1053–1059. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ding Y, Chen B, Wang S, et al:
Overexpression of Tiam1 in hepatocellular carcinomas predicts poor
prognosis of HCC patients. Int J Cancer. 124:653–658. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao L, Liu Y, Sun X, He M and Ding Y:
Overexpression of T lymphoma invasion and metastasis 1 predict
renal cell carcinoma metastasis and overall patient survival. J
Cancer Res Clin Oncol. 137:393–398. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu H, Shi G, Liu X, Wu H, Fan Q and Wang
X: Overexpression of Tiam1 predicts poor prognosis in patients with
esophageal squamous cell carcinoma. Oncol Rep. 25:841–848.
2011.PubMed/NCBI
|
|
26
|
Qi Y, Huang B, Yu L, Wang Q, Lan G and
Zhang Q: Prognostic value of Tiam1 and Rac1 overexpression in
nasopharyngeal carcinoma. ORL J Otorhinolaryngol Relat Spec.
71:163–171. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Minard ME, Kim LS, Price JE and Gallick
GE: The role of the guanine nucleotide exchange factor Tiam1 in
cellular migration, invasion, adhesion and tumor progression.
Breast Cancer Res Treat. 84:21–32. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang HM and Wang J: Expression of Tiam1 in
lung cancer and its clinical significance. Asian Pac J Cancer Prev.
13:613–615. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Moriarty CH, Pursell B and Mercurio AM:
miR-10b targets Tiam1: implications for Rac activation and
carcinoma migration. J Biol Chem. 285:20541–20546. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cottonham CL, Kaneko S and Xu L: miR-21
and miR-31 converge on TIAM1 to regulate migration and invasion of
colon carcinoma cells. J Biol Chem. 285:35293–35302. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Deryugina EI and Quigley JP: Matrix
metalloproteinases and tumor metastasis. Cancer Metastasis Rev.
25:9–34. 2006. View Article : Google Scholar
|
|
32
|
Patan S: Vasculogenesis and angiogenesis.
Cancer Treat Res. 117:3–32. 2004. View Article : Google Scholar
|
|
33
|
Choong ML, Yang HH and McNiece I: MicroRNA
expression profiling during human cord blood-derived CD34 cell
erythropoiesis. Exp Hematol. 35:551–564. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xiong J, Du Q and Liang Z:
Tumor-suppressive microRNA-22 inhibits the transcription of
E-box-containing c-Myc target genes by silencing c-Myc binding
protein. Oncogene. 29:4980–4988. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhong D, Li Y, Peng Q, et al: Expression
of Tiam1 and VEGF-C correlates with lymphangiogenesis in human
colorectal carcinoma. Cancer Biol Ther. 8:689–695. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhuge Y and Xu J: Rac1 mediates type I
collagen-dependent MMP-2 activation. role in cell invasion across
collagen barrier. J Biol Chem. 276:16248–16256. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Itoh Y, Takamura A, Ito N, et al:
Homophilic complex formation of MT1-MMP facilitates proMMP-2
activation on the cell surface and promotes tumor cell invasion.
EMBO J. 20:4782–4793. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shi TY, Cheng X, Yu KD, et al: Functional
variants in TNFAIP8 associated with cervical cancer susceptibility
and clinical outcomes. Carcinogenesis. January 8–2013.(Epub ahead
of print).
|
|
39
|
Zhang G, Xia S, Tian H, et al: Clinical
significance of miR-22 expression in patients with colorectal
cancer. Med Oncol. 29:3108–3112. 2012. View Article : Google Scholar : PubMed/NCBI
|
